protein

NLRP3 INFLAMMASOME

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NLRP3 INFLAMMASOME: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

925Connections

19Hypotheses

22Analyses

50Outgoing

50Incoming

0Experiments

20Debates

No summary available yet.

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	NLRP3 INFLAMMASOME
CRID3	early selective inhibitor
MCC994	optimized analog
Associated Diseases	AGING, Alzheimer's Disease, APOPTOSIS, ATP, AUTISM
Known Drugs/Compounds	BERBERINE, EMPAGLIFLOZIN, FINGOLIMOD, FISETIN, MELATONIN, METFORMIN
Interactions	HSP90A, NAMO
KG Connections	344 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

NLRP3 Inflammasome

entity · 1114 words

→

Pathway Diagram

graph TD
    NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"] -->|"activates"| Microglia["Microglia"]
    style Microglia fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"] -->|"causes"| Neuroinflammation["Neuroinflammation"]
    style Neuroinflammation fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"] -->|"associated"| IL_1_["IL-1Beta"]
    style IL_1_ fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"] -->|"involved in"| Inflammatory_Diseases["Inflammatory Diseases"]
    style Inflammatory_Diseases fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"] -->|"associated"| Alzheimer_s_Disease["Alzheimer's Disease"]
    style Alzheimer_s_Disease fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"] -->|"involved in"| Glaucoma["Glaucoma"]
    style Glaucoma fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
    NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"] -->|"causes"| Retinal_Ganglion_Cell_Death["Retinal Ganglion Cell Death"]
    style Retinal_Ganglion_Cell_Death fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
    USP22["USP22"] -.->|"inhibits"| NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"]
    style USP22 fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    USP5["USP5"] -.->|"inhibits"| NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"]
    style USP5 fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    NF__B["NF-kappaB"] -->|"activates"| NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"]
    style NF__B fill:#1a2a3a,stroke:#81c784,stroke-width:1px,color:#fff
    __SYNUCLEIN["Alpha-SYNUCLEIN"] -->|"activates"| NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"]
    style __SYNUCLEIN fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    Macrophage["Macrophage"] -->|"expressed in"| NLRP3_INFLAMMASOME["NLRP3 INFLAMMASOME"]
    style Macrophage fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
    style NLRP3_INFLAMMASOME fill:#006494,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0,font-weight:bold

Outgoing (323)

Target	Relation	Type	Str
pyroptosis	mediates	process	0.96
Microglia	activates	cell_type	0.95
Neuroinflammation	contributes_to	process	0.95
Retinal Ganglion Cell Death	mediates	process	0.95
IL18	associated_with	protein	0.95
Retinal Ganglion Cell Death	contributes_to	phenotype	0.95
Pyroptosis	mediates	process	0.95
Caspase-1 Activation	activates	mechanism	0.93
IL1B	upregulates	gene	0.92
Alzheimer's disease	associated_with	disease	0.92
dementia progression	promotes	phenotype	0.92
Liver inflammation	contributes_to	process	0.90
Microglia	activates	cell_type	0.90
Retinal Ganglion Cell Death	causes	phenotype	0.90
Parkinson'S Disease	involved_in	disease	0.90
caspase-1 activation	causes	mechanism	0.90
IL-1beta release	causes	phenotype	0.90
IL-18 release	causes	phenotype	0.90
Alzheimer's Disease	associated_with	disease	0.90
Phagocytic Function	inhibits	process	0.90
Inflammatory Diseases	involved_in	disease	0.90
Inflammatory Diseases	involved_in	disease	0.90
Neuroinflammation	activates	process	0.90
IL-1beta	activates	protein	0.90
Il-18	activates	protein	0.90
neointima formation	promotes	process	0.90
IL-18	associated_with	protein	0.90
IL1B	upregulates	protein	0.90
pathological inflammation	promotes	process	0.90
GSDMD	activates	protein	0.90
Neuroinflammation	causes	process	0.90
AUTOPHAGY	inhibited_by	process	0.90
Inflammatory Diseases	involved_in	disease	0.90
Neuroinflammation	activates	process	0.90
neuroinflammation	promotes	process	0.90
IL-1Β	associated_with	protein	0.90
Caspase-1 Activation	activates	process	0.90
Neuroinflammation	causes	process	0.90
IL-1Β	associated_with	protein	0.90
Pyroptosis	associated_with	process	0.90
Pyroptosis	activates	process	0.90
neuroinflammation	drives	process	0.90
IL18	upregulates	protein	0.90
Glaucoma	involved_in	disease	0.90
Neuroinflammation	mediates	process	0.90
alpha-synuclein	activates	protein	0.90
CASP1	activates	protein	0.88
IL1B	activates	protein	0.88
cognitive decline	promotes	phenotype	0.88
Preeclampsia	contributes_to	disease	0.88

Incoming (602)

Source	Relation	Type	Str
NLRP3	component_of	protein	0.95
Tlr2 Inhibition	suppresses	mechanism	0.95
GS-1	suppresses	compound	0.95
Neutrophil Extracellular Traps	activates	process	0.95
HDAC3	promotes	gene	0.95
Kaempferol	inhibits	compound	0.95
ZFP36	inhibits	gene	0.95
Carnosic Acid	inhibits	compound	0.95
TLR2	activates	gene	0.95
small-molecule inhibitors	inhibits	drug	0.95
Ciliatoside A	inhibits	compound	0.95
Polygala Saponins	inhibits	compound	0.95
REV-ERBα	inhibits	protein	0.95
Pg OMVs	activates	compound	0.95
Usp9X Suppression	inhibits	mechanism	0.95
USP9X	regulates	gene	0.95
NLRP3	involved_in	protein	0.95
A20	inhibits	protein	0.93
NEK7	activates	protein	0.92
GS-1	inhibits	compound	0.92
Ruxolitinib	inhibits	drug	0.92
Donepezil	associated_with	drug	0.90
HSP90A	activates	gene	0.90
alpha-synuclein fibrils	activates	protein	0.90
31284572	activate	paper	0.90
USP5	attenuates	gene	0.90
31284572	mediates	paper	0.90
Young plasma	modulates	compound	0.90
SEVOFLURANE	activates	compound	0.90
TFEB	inhibits	protein	0.90
LCN2	activates	protein	0.90
APOE4	activates	gene	0.90
cathepsin B	activates	protein	0.90
38421496	includes and activates	paper	0.90
CLEC16A	inhibits	gene	0.90
39904963	activates	paper	0.90
NLRP3	part_of	gene	0.90
38989642	key pathway in	paper	0.90
AMPK	inhibits	protein	0.90
DFV890	inhibits	drug	0.90
MCC940	inhibits	drug	0.90
SMPD1	activates	gene	0.90
Baohuoside I	inhibits	drug	0.90
Mitophagy	inhibits	process	0.90
Frostbite Injury	upregulates	disease	0.88
autophagy-lysosomal pathway	downstream_of	pathway	0.88
Biomechanical Strain	activates	process	0.88
Mitochondrial Damage	activates	process	0.88
Biomechanical Strain	activates	process	0.88
NF-κB	activates	pathway	0.87

Targeting Hypotheses (19)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S	0.822	neurodegeneration	What are the mechanisms by which gut mic
NLRP3 inflammasome amplification across AD and PD proteinopa	0.800	multi	Cross-disease neurodegeneration mechanis
NLRP3 Inflammasome Inhibition for Neuroprotection in Parkins	0.720	neurodegeneration	Test
NLRP3 Inflammasome Lock Perpetuates Senescence-Associated In	0.720	neurodegeneration	What molecular mechanisms drive microgli
C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macropha	0.631	neuroinflammation	What are the specific molecular mechanis

Galectin-3 deletion attenuates NLRP3 inflammasome activation	0.625	neuroscience	Lysosomal dysfunction and cathepsin leak
NLRP3 Inflammasome Priming Converts SCFA-Sensitive Pyroptosi	0.620	neurodegeneration	How does gut microbiome dysbiosis contri
Selective cathepsin B inhibition prevents cathepsin leakage-	0.620	neuroscience	Lysosomal dysfunction and cathepsin leak
NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1	0.610	neurodegeneration	Test Preregistration Analysis
Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppresses NLRP	0.590	neurodegeneration	What are the optimal oxygen pressure, du
NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumul	0.566	developmental-neurobiology	Do perinatal immune challenges create pe
NLRP3 Inflammasome Blockade as Upstream Intervention to Prev	0.566	neurodegeneration	Why have numerous phase 3 clinical trial
P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming	0.563	biomarkers	What biomarkers can reliably detect micr
TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inf	0.485	neuroinflammation	Immune atlas neuroinflammation analysis
Sub-antidepressant Doses Suppress NLRP3 Inflammasome via P2X	0.465	-	What is the minimum effective dose of tr
STING-Mediated NLRP3 Inflammasome Priming in ALS Microglia	0.380	neuroinflammation	Immune atlas neuroinflammation analysis
Circulating hs-CRP as Disease-Modifying Target via Astrocyti	0.380	immunomics	Systemic immune profiling in neurodegene
NLRP3 Inflammasome Suppression via Selective Caspase-1 Inhib	0.105	neurodegeneration	Neuroinflammation Biomarker Panel for Ea
Microglial NLRP3 Inflammasome as Circadian-Specific Drug Tar	0.000	-	Can circadian interventions selectively

Mentioning Analyses (22)

Scientific analyses that reference this entity

Cross-disease neurodegeneration mechanism synthesis

neurodegeneration | 2026-04-28 | 17 hypotheses Top: 0.828

Test Preregistration Analysis

neurodegeneration | 2026-04-27 | 7 hypotheses Top: 0.710

Gut-Brain Axis in Parkinson's Disease: Molecular Mechanisms, Neuroinflammation,

neurodegeneration | 2026-04-26 | 4 hypotheses Top: 0.630

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

neurodegeneration | 2026-04-24 | 6 hypotheses Top: 0.670

Microglial subtypes in neurodegeneration — friend vs foe

neurodegeneration | 2026-04-17 | 7 hypotheses Top: 0.685

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (9)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Interaction between autophagy and the NLRP3 inflammasome in Alzheimer's and Park [PMID:36262883]	Unknown	Frontiers in aging neuroscienc	2023
Inhibition of autophagy in microglia and macrophages exacerbates innate immune r [PMID:36652438]	Hegdekar N, Sarkar C, Bustos S, Ritzel R	Autophagy	2023
Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's [PMID:37029500]	Yan YQ, Zheng R, Liu Y, Ruan Y, Lin ZH,	Aging cell	2023
Microglial NLRP3 inflammasome activates neurotoxic astrocytes in depression-like [PMID:36288697]	Li S, Fang Y, Zhang Y, Song M, Zhang X,	Cell reports	2022
Biomarker of Neuroinflammation in Parkinson's Disease. [PMID:35456966]	Liu TW, Chen CM, Chang KH	Int J Mol Sci	2022
NLRP3 inflammasome activation drives tau pathology. [PMID:31748742]	["Ising C", "Venegas C", "Zhang S", "Sch	Nature	2019
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodeg [PMID:30381407]	Gordon R, Albornoz EA, Christie DC, Lang	Science translational medicine	2018
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS [PMID:23254930]	Heneka MT, Kummer MP, Stutz A, Delekate	Nature	2013
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS [PMID:23254930]	["Heneka Michael T", "Kummer Markus P",	Nature	2013

Debates (20)

Multi-agent debates referencing this entity

Which AD, PD, ALS, and FTD mechanisms recur across disease boundaries and yield

closed · Rounds: 4 · Score: 0.72 · 2026-04-28

Test question for preregistration

closed · Rounds: 4 · Score: 0.77 · 2026-04-28

Hypothesis debate: Microbial Inflammasome Priming Prevention

closed · Rounds: 4 · Score: 0.48 · 2026-04-27

Hypothesis debate: SCFA Deficiency Disrupts Microglial Homeostasis and Promotes

closed · Rounds: 4 · Score: 0.60 · 2026-04-26

Hypothesis debate: Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propag

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Enteric Nervous System Dysfunction as Self-Reinforcing Pathol

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

What are the key molecular mechanisms by which gut microbiome dysbiosis drives n

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

closed · Rounds: 4 · Score: 0.63 · 2026-04-24

What is the role of microglial synaptic pruning in Alzheimer's disease and other

closed · Rounds: 4 · Score: 0.68 · 2026-04-22

Related Research

Hypotheses and analyses mentioning NLRP3 INFLAMMASOME in their description or question text

Galectin-3 deletion attenuates NLRP3 inflammasome activation downstream of lysos

Score: 0.625 · neuroscience · 2026-04-22

**Molecular Mechanism and Rationale** Galectin-3 (LGALS3) functions as a critical molecular sensor and platform orchest

NLRP3 Inflammasome Priming Converts SCFA-Sensitive Pyroptosis into Chronic IL-1β

Score: 0.620 · neurodegeneration · 2026-04-26

Gut-derived bacterial components (LPS, MDP) provide Signal 1 for NLRP3 inflammasome priming via TLR4/TLR2/NOD2, inducing

Selective cathepsin B inhibition prevents cathepsin leakage-mediated NLRP3 infla

Score: 0.620 · neuroscience · 2026-04-22

## Mechanistic Overview Selective cathepsin B inhibition prevents cathepsin leakage-mediated NLRP3 inflammasome activati

NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1β Suppression

Score: 0.610 · neurodegeneration · 2026-04-28

NLRP3 inflammasome activation releases IL-1β, driving complement cascade upregulation and synapse elimination. MCC950 or

Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppresses NLRP3 inflammasome and s

Score: 0.590 · neurodegeneration · 2026-04-25

This hypothesis proposes that HBOT reduces ROS-mediated NF-κB activation and NLRP3 inflammasome assembly, promoting anti

NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumulation

Score: 0.566 · developmental-neurobiology · 2026-04-21

## Mechanistic Overview NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumulation starts from the claim that mod

NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplificati

Score: 0.566 · neurodegeneration · 2026-04-16

## Mechanistic Overview NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplification starts from t

P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming

Score: 0.563 · biomarkers · 2026-04-22

## Mechanistic Overview P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming starts from the claim that modulatin

TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inflammasome Regulation

Score: 0.485 · neuroinflammation · 2026-04-21

## Mechanistic Overview TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inflammasome Regulation starts from the

Sub-antidepressant Doses Suppress NLRP3 Inflammasome via P2X7 Receptor Blockade

Score: 0.465 · unknown disease · 2026-04-26

Trazodone acts as a weak antagonist at P2X7 purinergic receptors (IC50 ~3 micromolar), suppressing microglial NLRP3 infl

STING-Mediated NLRP3 Inflammasome Priming in ALS Microglia

Score: 0.380 · neuroinflammation · 2026-04-26

This hypothesis proposes that cytoplasmic mtDNA released from TDP-43-damaged mitochondria in ALS activates the cGAS-STIN

Circulating hs-CRP as Disease-Modifying Target via Astrocytic NLRP3 Inflammasome

Score: 0.380 · immunomics · 2026-04-27

Elevated circulating high-sensitivity C-reactive protein (hs-CRP) serves as a disease-modifying target through direct ac

NLRP3 Inflammasome Suppression via Selective Caspase-1 Inhibition

Score: 0.105 · neurodegeneration · 2026-04-18

## Mechanistic Overview NLRP3 Inflammasome Suppression via Selective Caspase-1 Inhibition starts from the claim that mod

Microglial NLRP3 Inflammasome as Circadian-Specific Drug Target

Score: 0.000 · unknown disease · 2026-04-28

The NLRP3 inflammasome exhibits circadian oscillations regulated by BMAL1-dependent acetylation. Selective microglial ta

NLRP3 INFLAMMASOME

Understanding Entity Pages

Wiki Pages (1)

NLRP3 Inflammasome

Pathway Diagram

Outgoing (323)

Incoming (602)

Targeting Hypotheses (19)

Mentioning Analyses (22)

Cross-disease neurodegeneration mechanism synthesis

Test Preregistration Analysis

Gut-Brain Axis in Parkinson's Disease: Molecular Mechanisms, Neuroinflammation,

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

Microglial subtypes in neurodegeneration — friend vs foe

Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma

Gut Microbiome Analysis in Parkinson's Disease

Is APOE4's reduced lipid binding pathogenic or a compensatory evolutionary adapt

Does TRPML1 enhancement cause therapeutic benefit or paradoxical lysosomal dysfu

Systemic immune profiling in neurodegeneration: peripheral inflammation as drive

How does APOE4's beneficial immune function reconcile with its established role

What are the optimal temporal windows for TREM2 inhibition vs activation in Alzh

Can circadian interventions selectively target microglia without affecting other

What specific astrocyte-derived factors can 'erase' pathological microglial memo

How does APOE4 mechanistically increase TDP-43 pathology frequency in Alzheimer'

How do perivascular cells specifically recognize and respond to amyloid-β to upr

Lysosomal dysfunction and cathepsin leakage in Alzheimer disease progression

Neuroinflammation and microglial priming in early Alzheimer's Disease

Immune atlas neuroinflammation analysis in neurodegeneration

Synaptic pruning by microglia in neurodegeneration

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Experiments (0)

Related Papers (9)

Debates (20)

Which AD, PD, ALS, and FTD mechanisms recur across disease boundaries and yield

Test question for preregistration

Hypothesis debate: Microbial Inflammasome Priming Prevention

Hypothesis debate: SCFA Deficiency Disrupts Microglial Homeostasis and Promotes

Hypothesis debate: Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propag

Hypothesis debate: Enteric Nervous System Dysfunction as Self-Reinforcing Pathol

Hypothesis debate: LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target

What are the key molecular mechanisms by which gut microbiome dysbiosis drives n

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects

What is the role of microglial synaptic pruning in Alzheimer's disease and other

Related Research

Galectin-3 deletion attenuates NLRP3 inflammasome activation downstream of lysos

NLRP3 Inflammasome Priming Converts SCFA-Sensitive Pyroptosis into Chronic IL-1β

Selective cathepsin B inhibition prevents cathepsin leakage-mediated NLRP3 infla

NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1β Suppression

Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppresses NLRP3 inflammasome and s

NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumulation

NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplificati

P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming

TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inflammasome Regulation

Sub-antidepressant Doses Suppress NLRP3 Inflammasome via P2X7 Receptor Blockade

STING-Mediated NLRP3 Inflammasome Priming in ALS Microglia

Circulating hs-CRP as Disease-Modifying Target via Astrocytic NLRP3 Inflammasome

NLRP3 Inflammasome Suppression via Selective Caspase-1 Inhibition

Microglial NLRP3 Inflammasome as Circadian-Specific Drug Target